Información de Dynavax Technologies Corp, dividendo de Dynavax Technologies Corp, actividades de los accionistas y más

Más Datos de Dynavax Technologies Corp Compañía

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Información de Dynavax Technologies Corp



Símbolo de cotizaciónDVAX

Nombre de la empresaDynavax Technologies Corp

Fecha de salida a bolsaFeb 19, 2004

Director ejecutivoSpencer (Ryan)

Número de empleados405

Tipo de seguridadOrdinary Share

Fin del año fiscalFeb 19

Dirección2100 Powell Street

CiudadEMERYVILLE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal94608

Teléfono15108485100

Sitio Webhttps://www.dynavax.com/

Símbolo de cotizaciónDVAX

Fecha de salida a bolsaFeb 19, 2004

Director ejecutivoSpencer (Ryan)

Ejecutivos de Dynavax Technologies Corp



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Ryan Spencer

Chief Executive Officer, Director

396.09K

+118415.00%

Mr. David F. Novack

Chief Operating Officer, Senior Vice President

109.97K

--

Dr. Robert (Rob) Janssen, M.D.

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

74.92K

--

Mr. John L. Slebir

Senior Vice President, General Counsel

63.47K

+32056.00%

Ms. Kelly MacDonald, CPA

Chief Financial Officer, Senior Vice President

56.49K

+30977.00%

Ms. Elaine D. Sun

Independent Director

29.86K

+5758.00%

Dr. Peter R. Paradiso, Ph.D.

Independent Director

24.83K

+5758.00%

Dr. Daniel L. (Dan) Kisner, M.D.

Independent Director

23.33K

+5758.00%

Mr. Brent MacGregor

Independent Director

21.83K

+5758.00%

Mr. Joseph Metzinger

Vice President, Chief Accounting Officer

7.13K

+7129.00%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Ryan Spencer

Chief Executive Officer, Director

396.09K

+118415.00%

Mr. David F. Novack

Chief Operating Officer, Senior Vice President

109.97K

--

Dr. Robert (Rob) Janssen, M.D.

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

74.92K

--

Mr. John L. Slebir

Senior Vice President, General Counsel

63.47K

+32056.00%

Ms. Kelly MacDonald, CPA

Chief Financial Officer, Senior Vice President

56.49K

+30977.00%

Ms. Elaine D. Sun

Independent Director

29.86K

+5758.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

Por negocioUSD

Nombre

Ganancia

Proporción

HEPLISAV-B

89.95M

94.81%

Other revenue

4.92M

5.19%

Por regiónUSD

Nombre

Ganancia

Proporción

US

94.69M

99.81%

Non-US

183.00K

0.19%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

HEPLISAV-B

89.95M

94.81%

Other revenue

4.92M

5.19%

Estadísticas de accionistas

Actualizado: dom., 16 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

Deep Track Capital LP

13.83%

BlackRock Institutional Trust Company, N.A.

12.93%

The Vanguard Group, Inc.

7.04%

State Street Investment Management (US)

5.53%

Millennium Management LLC

3.98%

Otro

56.68%

Accionistas

Proporción

Deep Track Capital LP

13.83%

BlackRock Institutional Trust Company, N.A.

12.93%

The Vanguard Group, Inc.

7.04%

State Street Investment Management (US)

5.53%

Millennium Management LLC

3.98%

Otro

56.68%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

35.91%

Hedge Fund

35.76%

Investment Advisor/Hedge Fund

22.50%

Research Firm

6.27%

Pension Fund

1.19%

Individual Investor

0.84%

Bank and Trust

0.37%

Private Equity

0.04%

Sovereign Wealth Fund

0.03%

Participación institucional



Actualizado: lun., 8 de dic

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

546

115.83M

109.38%

+66.95K

2025Q3

565

115.78M

113.44%

+813.17K

2025Q2

563

116.95M

120.36%

-13.51M

2025Q1

558

131.20M

118.77%

-16.39M

2024Q4

550

133.28M

116.08%

-4.50M

2024Q3

545

132.56M

115.53%

-2.40M

2024Q2

531

134.71M

114.10%

-1.03M

2024Q1

527

135.87M

107.19%

-4.14M

2023Q4

514

128.04M

106.45%

-253.89K

2023Q3

500

128.23M

106.72%

-886.82K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Deep Track Capital LP

15.73M

13.83%

--

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

14.70M

12.93%

-1.10M

-6.96%

Sep 30, 2025

The Vanguard Group, Inc.

8.08M

7.11%

-327.20K

-3.89%

Sep 30, 2025

State Street Investment Management (US)

6.29M

5.53%

-110.47K

-1.73%

Sep 30, 2025

Millennium Management LLC

4.53M

3.98%

+2.92M

+180.74%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

3.57M

3.14%

-77.23K

-2.12%

Sep 30, 2025

Chicago Capital, LLC

4.31M

3.79%

-919.11K

-17.58%

Sep 30, 2025

Renaissance Technologies LLC

3.14M

2.76%

+252.02K

+8.73%

Sep 30, 2025

Two Sigma Investments, LP

3.01M

2.65%

-784.25K

-20.67%

Sep 30, 2025

Geode Capital Management, L.L.C.

2.53M

2.23%

-158.37K

-5.89%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Invesco Biotechnology & Genome ETF

2.91%

Virtus LifeSci Biotech Products ETF

1.58%

ETC 6 Meridian Small Cap Equity ETF

1.21%

Invesco S&P SmallCap Health Care ETF

0.62%

ETC 6 Meridian Low Beta Equity Strategy ETF

0.46%

Pacer US Small Cap Cash Cows Growth Leaders ETF

0.42%

State Street SPDR S&P Biotech ETF

0.41%

Themes US Small Cap Cash Flow Champions ETF

0.35%

Royce Quant Small-Cap Quality Value ETF

0.29%

Direxion Daily S&P Biotech Bull 3X Shares

0.25%

Invesco Biotechnology & Genome ETF

Proporción2.91%

Virtus LifeSci Biotech Products ETF

Proporción1.58%

ETC 6 Meridian Small Cap Equity ETF

Proporción1.21%

Invesco S&P SmallCap Health Care ETF

Proporción0.62%

ETC 6 Meridian Low Beta Equity Strategy ETF

Proporción0.46%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proporción0.42%

State Street SPDR S&P Biotech ETF

Proporción0.41%

Themes US Small Cap Cash Flow Champions ETF

Proporción0.35%

Royce Quant Small-Cap Quality Value ETF

Proporción0.29%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.25%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos